IGC Pharma Welcomes Strategic Investment from Advisors
Summary
The shares are unregistered, subject to 144 restrictions, and are not tradable for a six-month period.The funds will support general corporate purposes and the Companys advancement of CALMA Phase 2 clinical trial on agitation in Alzheimers disease.Ram Mukunda, CEO commented, "Were pleased to see this strong vote of confidence from our new advisors. He led the development of the American Airlines Center in Dallas Texas and has been a public commentator on finance, politics, global strategy, and brings decades of leadership in venture capital, private equity, and public-private partnerships. Mr. Zaccanelli will support IGC Pharma in identifying and cultivating strategic partnerships, as well as advising on the Companys engagement with brand ambassador and key influencers in the Alzheimers space.Robert K. Coughlin, former President and CEO of MassBio, has been a champion of biotech innovation and recently received the 2025 Henri A. Termeer Innovative Leadership Award for his enduring contributions to the life sciences ecosystem. His deep empathy for vulnerable populations, particularly the elderly, aligns closely with IGC Pharmas mission to support Alzheimers patients and caregivers. With 30 patent filings and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.This press release contains forward-looking statements.